Kexi Pharmaceutical announced that the confirmatory Phase II clinical trial of its Shruti Kyolonsay injection has completed enrollment and randomization in China. The trial aims to evaluate the efficacy and safety of the drug in treating advanced gastric/esophageal gastroesophageal junction adenocarcinoma patients who express positive Claudin18.2 and have undergone at least two treatments. Shruti Kyolonsay injection is a self CAR-T cell candidate product targeting Claudin18.2 protein, which has been recognized by the US FDA's "Advanced Therapy for Regenerative Medicine" and has priority drug qualification from the European Medicines Agency. Kexi Pharmaceutical focuses on innovative CAR-T cell therapy for the treatment of hematological malignancies and solid tumors, and has established a research and development platform from target discovery to commercial-scale production.

Kexi Pharmaceutical announced that the confirmatory Phase II clinical trial of its Shruti Kyolonsay injection has completed enrollment and randomization in China. The trial aims to evaluate the efficacy and safety of the drug in treating advanced gastric/esophageal gastroesophageal junction adenocarcinoma patients who express positive Claudin18.2 and have undergone at least two treatments. Shruti Kyolonsay injection is a self CAR-T cell candidate product targeting Claudin18.2 protein, which has been recognized by the US FDA's "Advanced Therapy for Regenerative Medicine" and has priority drug qualification from the European Medicines Agency. Kexi Pharmaceutical focuses on innovative CAR-T cell therapy for the treatment of hematological malignancies and solid tumors, and has established a research and development platform from target discovery to commercial-scale production.